HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

lactogangliotetraosylceramide

Also Known As:

LcGg4

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycolipids: 2799
    - Glycosphingolipids: 1659
      - Acidic Glycosphingolipids: 20
        Gangliosides: 3319
        lactogangliotetraosylceramide: 2
Lipids: 114793
- Glycolipids: 2799
  - Glycosphingolipids: 1659
    - Acidic Glycosphingolipids: 20
      - Gangliosides: 3319
        lactogangliotetraosylceramide: 2
- Membrane Lipids: 1591
  - Sphingolipids: 3208
    - Glycosphingolipids: 1659
      - Acidic Glycosphingolipids: 20
        Gangliosides: 3319
        lactogangliotetraosylceramide: 2

Experts

1.	Chen, Sixue: 1 article (06/2022)
2.	Gao, Tianqi: 1 article (06/2022)
3.	Guo, Zhongwu: 1 article (06/2022)
4.	Huang, Fanran: 1 article (06/2022)
5.	Li, Qingjiang: 1 article (06/2022)
6.	Lott, Aneirin A: 1 article (06/2022)
7.	Olivos, Hernando J: 1 article (06/2022)
8.	Rohokale, Rajendra: 1 article (06/2022)

Related Diseases

1.	Neoplasms (Cancer) 06/27/2022 - "LcGg4, a neutral glycosphingolipid (GSL) and cancer antigen, its epimers GalNAc-LcGg4 and GlcNAc-LcGg4, and three lipid forms of GalNAc-LcGg4 were studied by mass spectrometry (MS). " 01/25/1987 - "Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. "
2.	Leukemia 01/25/1987 - "Thus, the antibodies were found to be useful probes to detect lactogangliotetraosylceramide expressed in undifferentiated M1 leukemia cells, which disappears on induced differentiation. " 01/25/1987 - "Monoclonal antibodies directed to chemically synthesized lactogangliotetraosylceramide, a leukemia-associated antigen having a novel branching structure." 01/25/1987 - "Murine leukemia cells (M1), in their undifferentiated state, have been characterized by the presence of cancer-associated lactoganglio-series glycolipids, one of which was identified as lactogangliotetraosylceramide (LcGg4) having a novel branching at the II-Gal of lactosylceramide through GlcNAc beta 1----3 and GalNAc beta 1----4 linkage, as shown below (Kannagi, R., Levery, S.B., and Hakomori, S. "

Related Drugs and Biologics

1.	Antigens
2.	lactogangliotetraosylceramide
3.	Lipids
4.	Glycosphingolipids
5.	Glycolipids
6.	Monoclonal Antibodies
7.	Antibodies
8.	CDw17 antigen (lactosylceramide)